July 30, 2018 10:32 AM EDT

Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope

John Carroll

Editor & Founder

→ Shares of Israel’s Redhill BioPharma $RDHL spiked Monday morning — then quickly began to slide back — after the biotech laid out data demonstrating how …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope

John Carroll

Editor & Founder

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Takeda announces handful of pipeline cuts in effort to ‘pivot resources’

GSK awaits Nucala decision after FDA target date passes

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'

AstraZeneca loses appeals court fight over IRA drug price negotiations

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Red­hill spikes — briefly — on pos­i­tive Crohn's da­ta; Dai­ichi inks glob­al li­cens­ing deal with Gly­co­tope

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Redhill spikes — briefly — on positive Crohn's data; Daiichi inks global licensing deal with Glycotope